Women’s Health
Navigating New Horizons in Endometrial Cancer
Expert Insights and Patient-Centered Care
As of 2024, endometrial cancer also called the cancer of the uterus, is the only malignancy for which survival has fallen over the past four decades. The mortality rates of this known global problem continue to increase by 2% per year.
In the United States alone, about 67,880 new cases of endometrial cancers are expected to be diagnosed by the end of 2024. It by far ranks in the 6th place in the world among cancers affecting women.
These relatively alarming statistics are significant, highlighting the importance of the Need for advancement in treatment and early detection.
The good news is that the treatment landscape around endometrial cancer is rapidly expanding.
One of the most recent developments is the approval of the Imfinzi regimen by the FDA. Produced by AstraZeneca, this medication is designed for advanced and recurrent cases. This move by the FDA offers new hope for affected women with uterine cancer.
The sole purpose of maximizing efficiency in endometrial cancer therapy rests in personalizing it. However, this requires an understanding of the molecular subtypes within the disease, which is crucial in guiding…
